140 related articles for article (PubMed ID: 11699394)
21. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
22. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
Warren TL; Weiner GJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):93-7. PubMed ID: 11842395
[TBL] [Abstract][Full Text] [Related]
23. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
24. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.
Sparwasser T; Koch ES; Vabulas RM; Heeg K; Lipford GB; Ellwart JW; Wagner H
Eur J Immunol; 1998 Jun; 28(6):2045-54. PubMed ID: 9645386
[TBL] [Abstract][Full Text] [Related]
25. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
26. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
27. Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step.
Macfarlane DE; Manzel L; Krieg AM
Immunology; 1997 Aug; 91(4):586-93. PubMed ID: 9378499
[TBL] [Abstract][Full Text] [Related]
28. CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.
Bernard MP; Phipps RP
Clin Immunol; 2007 Nov; 125(2):138-48. PubMed ID: 17728187
[TBL] [Abstract][Full Text] [Related]
29. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
Hagn M; Blackwell SE; Beyer T; Ebel V; Fabricius D; Lindner S; Stilgenbauer S; Simmet T; Tam C; Neeson P; Trapani JA; Schrezenmeier H; Weiner GJ; Jahrsdörfer B
Int Immunol; 2014 Jul; 26(7):383-95. PubMed ID: 24497611
[TBL] [Abstract][Full Text] [Related]
30. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.
Carpentier AF; Auf G; Delattre JY
Front Biosci; 2003 Jan; 8():e115-27. PubMed ID: 12456326
[TBL] [Abstract][Full Text] [Related]
31. Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia.
Jahrsdörfer B; Blackwell SE; Wooldridge JE; Taylor CM; Weiner GJ
Oligonucleotides; 2005; 15(1):51-9. PubMed ID: 15788900
[TBL] [Abstract][Full Text] [Related]
32. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.
Zwiorek K; Bourquin C; Battiany J; Winter G; Endres S; Hartmann G; Coester C
Pharm Res; 2008 Mar; 25(3):551-62. PubMed ID: 17912489
[TBL] [Abstract][Full Text] [Related]
33. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
Warren TL; Dahle CE; Weiner GJ
Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
[TBL] [Abstract][Full Text] [Related]
34. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
[TBL] [Abstract][Full Text] [Related]
35. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles.
Kerkmann M; Lochmann D; Weyermann J; Marschner A; Poeck H; Wagner M; Battiany J; Zimmer A; Endres S; Hartmann G
Oligonucleotides; 2006; 16(4):313-22. PubMed ID: 17155907
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
37. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
[TBL] [Abstract][Full Text] [Related]
38. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
39. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.
Lenert P; Stunz L; YI AK; Krieg AM; Ashman RF
Antisense Nucleic Acid Drug Dev; 2001 Aug; 11(4):247-56. PubMed ID: 11572601
[TBL] [Abstract][Full Text] [Related]
40. In vivo immunostimulatory effects of CpG ODN in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Mol Immunol; 2007 Feb; 44(6):1238-44. PubMed ID: 16908068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
